Analytical and Bioanalytical Chemistry ( IF 3.8 ) Pub Date : 2021-08-23 , DOI: 10.1007/s00216-021-03583-2 Sophie Bravo-Veyrat 1 , Gérard Hopfgartner 1
|
Liquid chromatography coupled to mass spectrometry (LC-MS) is the gold standard in bioanalysis for the development of quantitative assays to support drug development or therapeutic drug monitoring. High-throughput and low-cost gene sequencing have enabled a paradigm shift from one treatment fits all to personalized medicine (PM). However, gene monitoring provides only partial information about the health state. The full picture requires the combination of gene monitoring with the screening of exogenous compounds, metabolites, lipids, and proteins. This critical review discusses how mass spectrometry–based technologies and approaches including separation sciences, ambient ionization, and ion mobility are/could be used to support high-throughput bioanalysis of endogenous end exogenous low molecular weight compounds. It includes also various biological sample types (from blood to expired air), and various sample preparation techniques.
Graphical abstract
中文翻译：
基于质谱的低分子量化合物高通量生物分析：我们准备好支持个性化医疗了吗？
液相色谱与质谱联用 (LC-MS) 是生物分析中的金标准，用于开发支持药物开发或治疗药物监测的定量分析。高通量和低成本的基因测序使范式从一种万能疗法转变为个性化医疗 (PM)。但是，基因监测仅提供有关健康状况的部分信息。全面的情况需要将基因监测与外源化合物、代谢物、脂质和蛋白质的筛选相结合。这篇批判性综述讨论了基于质谱的技术和方法，包括分离科学、环境电离和离子淌度如何/可以用于支持内源性末端外源性低分子量化合物的高通量生物分析。
京公网安备 11010802027423号